Lupin Q1 FY24 Growth Metrics and ESG Goals

Lupin Today Operating from a position of strength Global Presence 13th Local Leadership LUPIN Largest Generic Company 3rd Largest in the US India Pharma 6th Market 37% INDIA (by prescriptions³) Geographically Diverse (FY23 Sales) 8% Developed Markets (by sales³) 8th Brazil and Mexico (by sales¹) $2 bn Annual sales in FY23 $233mn EBITDA in FY23 21,300+ Lupinytts Reaching lives in 100+ countries Largest 4th Australia Gx (by sales) With Global Infrastructure And Growing Sustainably² ~13% reduction in Scope 1 and 2 emissions Adding 22MW Renewable energy capacity in FY24 15 Manufacturing 7 Sites R&D Sites Renewable energy share of ~5% across India, the US, Netherlands, Largest South 32% US 14% Africa Gx (by sales³) Emerging 7% Developing Adjacencies Markets ΑΡΙ 1 Global ranking based on LTM Mar23 sales | 2 Reduction from base of FY230 13 IQVIA Qtr Jun-23 14 IQVIA MAT Mar-23 15 IQVIA MAT may-23 12

View entire presentation